Ingram, who steered the company through multiple drug approvals and controversies, will step aside as the company faces dwindling Elevidys sales and emerging competitors to its core business.
Ingram, who steered the company through multiple drug approvals and controversies, will step aside as the company faces dwindling Elevidys sales and emerging competitors to its core business.
